Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease
Christine Schofield, K Ray Chaudhuri, Camille Carroll, Jagdish C Sharma, Nicola Pavese, Jonathan Evans, Thomas Foltynie, Heinz Reichmann, Laura Zurowska, Patrício Soares-da-Silva, Andrew Lees, Christine Schofield, K Ray Chaudhuri, Camille Carroll, Jagdish C Sharma, Nicola Pavese, Jonathan Evans, Thomas Foltynie, Heinz Reichmann, Laura Zurowska, Patrício Soares-da-Silva, Andrew Lees
Abstract
Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.
Trial registration: ClinicalTrials.gov NCT02847442.
Keywords: Parkinson's disease; cost-saving; health economics; levodopa; motor fluctuations; opicapone.
Source: PubMed